DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 Stock Report

Market Cap: CN¥18.6b

DaShenLin Pharmaceutical Group Past Earnings Performance

Past criteria checks 2/6

DaShenLin Pharmaceutical Group has been growing earnings at an average annual rate of 7.9%, while the Consumer Retailing industry saw earnings growing at 5.1% annually. Revenues have been growing at an average rate of 18.7% per year. DaShenLin Pharmaceutical Group's return on equity is 11.7%, and it has net margins of 3.5%.

Key information

7.9%

Earnings growth rate

7.3%

EPS growth rate

Consumer Retailing Industry Growth12.8%
Revenue growth rate18.7%
Return on equity11.7%
Net Margin3.5%
Next Earnings Update31 Oct 2024

Recent past performance updates

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Recent updates

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Revenue & Expenses Breakdown

How DaShenLin Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:603233 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2425,8859077,31086
31 Mar 2425,3361,0687,07779
31 Dec 2324,5311,1666,82481
30 Sep 2324,1541,2876,71975
30 Jun 2323,5191,2396,61180
31 Mar 2322,5181,1486,43380
31 Dec 2221,2481,0366,29374
30 Sep 2219,2228965,92371
30 Jun 2218,4258605,70256
31 Mar 2217,3778355,43051
31 Dec 2116,7597915,19845
30 Sep 2116,4461,0134,91313
30 Jun 2115,6971,1134,65110
31 Mar 2115,2801,1224,4116
31 Dec 2014,5831,0624,1785
30 Sep 2013,5931,0143,8810
30 Jun 2012,8299173,6941
31 Mar 2011,9257993,5621
31 Dec 1911,1417033,4240
30 Sep 1910,6016743,2922
30 Jun 1910,0296243,1691
31 Mar 199,4045693,0531
31 Dec 188,8595322,9061
30 Sep 188,4215222,7100
30 Jun 188,0035152,5420
31 Mar 187,7185052,3930
31 Dec 177,4214752,2750
30 Sep 176,9924622,1520
30 Jun 176,8244582,0520
31 Mar 176,5454331,9600
31 Dec 166,2744301,8670
30 Jun 165,6814271,6650
31 Mar 165,4644151,5840
31 Dec 155,2653951,5410
31 Dec 144,5452661,3410
31 Dec 133,7071971,0710

Quality Earnings: 603233 has high quality earnings.

Growing Profit Margin: 603233's current net profit margins (3.5%) are lower than last year (5.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603233's earnings have grown by 7.9% per year over the past 5 years.

Accelerating Growth: 603233's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 603233 had negative earnings growth (-26.8%) over the past year, making it difficult to compare to the Consumer Retailing industry average (0.3%).


Return on Equity

High ROE: 603233's Return on Equity (11.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies